UA68332C2 - Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) - Google Patents

Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) Download PDF

Info

Publication number
UA68332C2
UA68332C2 UA98126370A UA98126370A UA68332C2 UA 68332 C2 UA68332 C2 UA 68332C2 UA 98126370 A UA98126370 A UA 98126370A UA 98126370 A UA98126370 A UA 98126370A UA 68332 C2 UA68332 C2 UA 68332C2
Authority
UA
Ukraine
Prior art keywords
polypeptide
omp106
sequence
catarrhalis
variants
Prior art date
Application number
UA98126370A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Publication of UA68332C2 publication Critical patent/UA68332C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
UA98126370A 1996-05-03 1997-04-28 Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) UA68332C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
PCT/US1997/007679 WO1997041731A1 (en) 1996-05-03 1997-04-28 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof

Publications (1)

Publication Number Publication Date
UA68332C2 true UA68332C2 (en) 2004-08-16

Family

ID=24577687

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98126370A UA68332C2 (en) 1996-05-03 1997-04-28 Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants)

Country Status (25)

Country Link
US (6) US7341727B1 (de)
EP (1) EP0900025B1 (de)
JP (2) JP4401437B2 (de)
CN (2) CN100415871C (de)
AR (1) AR006999A1 (de)
AT (1) ATE244016T1 (de)
AU (1) AU723528B2 (de)
BG (1) BG64832B1 (de)
BR (1) BR9711090A (de)
CA (1) CA2253636C (de)
CZ (1) CZ298034B6 (de)
DE (1) DE69723254T2 (de)
EA (1) EA002743B1 (de)
EE (1) EE04684B1 (de)
ES (1) ES2202624T3 (de)
GE (1) GEP20022695B (de)
HU (1) HU223004B1 (de)
NO (2) NO324816B1 (de)
NZ (1) NZ332896A (de)
PL (3) PL189375B1 (de)
SK (1) SK284812B6 (de)
TW (1) TW541314B (de)
UA (1) UA68332C2 (de)
WO (1) WO1997041731A1 (de)
ZA (1) ZA973809B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) * 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
BR0009166A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
DE60039108D1 (de) * 1999-05-24 2008-07-17 Glaxosmithkline Biolog Sa Neue verbindungen aus moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
ATE368686T1 (de) * 1999-09-14 2007-08-15 Glaxosmithkline Biolog Sa Polypeptide aus moraxella (branhamella) catarrhalis
GB9921691D0 (en) 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
ES2537737T3 (es) 2002-08-02 2015-06-11 Glaxosmithkline Biologicals S.A. Composiciones de vacuna que comprenden lipooligosacáridos de inmunotipo L2 y/o L3 de Neisseria meningitidis de IgtB
KR102564388B1 (ko) 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ES2809167T3 (es) 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
CA2652957A1 (en) * 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
KR101614938B1 (ko) 2007-07-12 2016-04-22 오럴 헬스 오스트레일리아 피티와이 엘티디 균막 치료
NZ582438A (en) * 2007-07-12 2012-03-30 Oral Health Australia Pty Ltd A composition for use in raising an immune response to p. gingivalis
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
EP3255057B1 (de) 2008-08-29 2020-03-18 Oral Health Australia Pty Ltd Prävention, behandlung und diagnose einer p.-gingivalis-infektion
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
CA2781556C (en) 2009-11-23 2015-05-19 Cyvek, Inc. Method and apparatus for performing assays
US9651568B2 (en) 2009-11-23 2017-05-16 Cyvek, Inc. Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US9216412B2 (en) 2009-11-23 2015-12-22 Cyvek, Inc. Microfluidic devices and methods of manufacture and use
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
WO2013134739A1 (en) 2012-03-08 2013-09-12 Cyvek, Inc. Microfluidic assay operating system and methods of use
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CA2792683A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
SG184310A1 (en) 2010-04-13 2012-10-30 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
WO2011137334A1 (en) * 2010-04-30 2011-11-03 The Research Foundation Of State University Of New York Compositions and methods for stimulating immune response against moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
US12551553B2 (en) 2018-11-29 2026-02-17 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3980044A1 (de) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponinreinigung
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
KR20240006541A (ko) 2021-04-09 2024-01-15 셀덱스 쎄라퓨틱스, 인크. Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (de) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Kontinuierliches verfahren zur herstellung von impfstoffen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) * 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) * 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
NO985113D0 (no) 1998-11-02
HUP9902695A2 (hu) 1999-12-28
CZ298034B6 (cs) 2007-05-30
ATE244016T1 (de) 2003-07-15
US7914795B2 (en) 2011-03-29
BG102983A (en) 2000-05-31
NO324816B1 (no) 2007-12-10
JP4401437B2 (ja) 2010-01-20
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
AR006999A1 (es) 1999-10-13
US20070087019A1 (en) 2007-04-19
HU223004B1 (hu) 2004-03-01
NZ332896A (en) 2000-05-26
PL330935A1 (en) 1999-06-07
EP0900025A1 (de) 1999-03-10
HK1021299A1 (en) 2000-06-09
JP2008161194A (ja) 2008-07-17
AU3118097A (en) 1997-11-26
AU723528B2 (en) 2000-08-31
US7576179B2 (en) 2009-08-18
CA2253636C (en) 2003-04-22
PL189375B1 (pl) 2005-07-29
GEP20022695B (en) 2002-05-27
PL189995B1 (pl) 2005-10-31
EE04684B1 (et) 2006-08-15
ES2202624T3 (es) 2004-04-01
CN1223549A (zh) 1999-07-21
ZA973809B (en) 1997-12-01
CN1222618C (zh) 2005-10-12
US20020177200A1 (en) 2002-11-28
HUP9902695A3 (en) 2001-02-28
HK1095358A1 (zh) 2007-05-04
EA002743B1 (ru) 2002-08-29
EP0900025B1 (de) 2003-07-02
CZ352498A3 (cs) 1999-06-16
EE9800373A (et) 1999-04-15
US7341727B1 (en) 2008-03-11
CA2253636A1 (en) 1997-11-13
BR9711090A (pt) 1999-08-17
EA199800973A1 (ru) 1999-06-24
US20100021492A1 (en) 2010-01-28
CN1800359A (zh) 2006-07-12
EP0900025A4 (de) 2000-01-05
SK284812B6 (sk) 2005-12-01
SK150998A3 (en) 1999-05-07
PL189374B1 (pl) 2005-07-29
CN100415871C (zh) 2008-09-03
DE69723254T2 (de) 2004-04-22
NO20063711L (no) 1998-12-28
US6214981B1 (en) 2001-04-10
WO1997041731A1 (en) 1997-11-13
US7128910B2 (en) 2006-10-31
DE69723254D1 (de) 2003-08-07
US20080145916A1 (en) 2008-06-19
JP2000510696A (ja) 2000-08-22
BG64832B1 (bg) 2006-06-30

Similar Documents

Publication Publication Date Title
UA68332C2 (en) Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants)
KR100361562B1 (ko) 프로테이나제k에대해내성을갖는네이쎄리아메닝기티디스의표면단백질
EA007409B1 (ru) Антигенные полипептиды стрептококков, способы их получения и применения
AU614718B2 (en) A neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US10603373B2 (en) Targets of Acinetobacter baumannii
RU2252224C2 (ru) Пептид со свойствами антигена neisseria meningitidis, кодирующий его полинуклеотид, вакцина для лечения или предотвращения заболеваний или состояний, вызванных neisseria meningitidis, (варианты), антитело, связывающееся с указанным пептидом
CN116063548B (zh) 一种融合蛋白KP-Ag1及其用作肺炎克雷伯菌疫苗抗原的应用
WO1993000358A1 (en) Pseudomonas exoenzyme s peptide composition and method
US7311917B2 (en) Moraxella catarrhalis protein, gene sequence and uses thereof
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
US20090246228A1 (en) Moraxella catarrhalis Proteins
CA2520386A1 (en) Nontypeable haemophilus influenzae virulence factors
KR20010044842A (ko) 백신 보조제로서 콜레라 독소 비 또는 장독소 비의펩타이드 단편
US6218147B1 (en) Haemophilus adhesin protein
KR100500000B1 (ko) 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
CA2182046A1 (en) Haemophilus adhesin protein
HK1095358B (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and use thereof
CN119185523A (zh) 预防b群脑膜炎球菌感染的广谱多联亚单位疫苗及其用途
WO2004104044A1 (ja) 抗体の製造方法